CREATING INNOVATIVE CANCER THERAPIES BY LEVERAGING UNDEREXPLOITED BIOLOGIC OPPORTUNITIES

Clinical Trials
Recruiting

Developing innovative internally discovered small molecule drug candidates as well as antibody candidates that target immuno-oncology pathways

learn more

We’re Hiring!
Growth

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology.

learn more

Press Releases
Recent News

Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

view all

MEDIA

Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

By Randy Osborne, Staff Writer

Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.

Keep Reading

PIPELINE

Clinical Program¹

PRINTABLE VERSION

1. Taiho has an option to Arcus’s programs in Japan and certain other Asian territories (excluding China) over a 5-year term.2. Pending listing on clinicaltrials.gov.3. Clinical collaboration with Genentech, Member of the Roche Group.4. Pegylated liposomal doxorubicin.5. Clinical collaboration with Infinity Pharmaceuticals.